Bristol-Myers Squibb consensus stabilizes, analysts see upside for the shares
Published on 06/23/2026 at 18:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 18:41.
Bristol-Myers Squibb (US1078421011) opens the new week on the New York Stock Exchange with a largely unchanged analyst stance. Consensus data point to a Hold rating on the shares with moderate upside potential based on current target prices.
What recent data show on BMY
On Tuesday mid-session, Bristol-Myers Squibb shares trade around 55 dollars on the NYSE, after a positive session on June 22 that saw a close near 54.70 dollars according to recent price data.
Market information from financial platforms indicates a market capitalization in the area of 111 billion dollars and a trailing price-earnings ratio around the mid-teens, reflecting the group’s position among large-cap U.S. pharmaceuticals alongside peers such as Pfizer and Merck.
Analyst ratings and targets in focus
According to current analyst summaries, Bristol-Myers Squibb carries an overall Hold signal, with an average target price in the low 60-dollar range implying mid-single-digit to low-double-digit upside from recent trading levels as of late June 2026. One aggregated view cites a target region slightly above 62 dollars per share, based on a composite of Wall Street forecasts that balances cautious and more constructive opinions on the stock.
Rating distributions compiled by analyst-tracking services show a mix of Buy, Hold and Sell recommendations, with Holds forming the largest block and Buys still representing a significant minority. While individual houses such as Goldman Sachs, JPMorgan or Morgan Stanley periodically adjust their stance, the current consensus picture remains relatively stable compared with earlier in the year, with no broad shift toward either aggressive downgrades or upgrades in recent weeks.
All news and analysis on the Bristol-Myers Squibb shares
Track fresh headlines, price data and regulatory filings for Bristol-Myers Squibb in one place on ad-hoc-news.de and via the company’s investor relations pages.
The products behind the pharma group
Bristol-Myers Squibb generates revenue primarily from prescription medicines in oncology, cardiovascular and immunology, including blockbuster therapies such as the cancer drug Opdivo and anticoagulant Eliquis. The portfolio also includes newer specialty products targeting autoimmune and hematology indications.
Where the shares trade today
The Bristol-Myers Squibb shares (US1078421011) trade on 2026-06-23, 16:41 on the NYSE at 55.25 dollars.
Key data on the Bristol-Myers Squibb shares
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- WKN: 850501
- Ticker: BMY
- Trading venue: NYSE
- Price (as of 2026-06-23, 16:41): 55.25 USD
- Market cap: 111.35 billion USD (as of 2026-06-23)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
